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93 Infection control in cystic ﬁbrosis: assessment of Pseudomonas
aeruginosa genotypes isolated from Italian children patients
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1Giannina Gaslini Institute, Genoa, Italy
Objectives: Chronic pulmonary infection with P. aeruginosa (PA) is responsible
for signiﬁcant mobidity and mortality in Cystic Fibrosis (CF). The means of
transmission of PA in CF affected patients have not been clearly established. Many
CF patients appear to acquire the organisms from the natural environment and not
from other CF patients. The 29% of CF patients acquired nonmucoid PA in the
ﬁrst 6 months of life. The aim of this study is to assess the genotypes of ﬁrst PA
isolated from Italian children patients attending contemporary Genoa CF center to
understand the type of acquisition/transmission.
Methods: The PA strains isolated of 28 young patients (range of age:
2 months-3 years) attending CF Genoa center were analysed and compared with
PA recovered from other CFGenoa patients and 55 environmental strains (11 from
hospital sinks, 44 from swimming pool and mineral water) by BOX-PCR A PA panel
control strains included: PA01, ATCC 27853, European clone C (EC), Manchester
Epidemic Strain (MES) and Liverpool Epidemic Strain (LES). The cluster analysis
was performed by “Gel Compar II”.
Results: The molecular proﬁles of 28 children patients are not correlated. The
comparison with other CF clinical, environmental and epidemic strains didn’t show
any genotypes correlated.
Conclusion: Environmental acquisition was not documented. The molecular proﬁle
suggests that person-to-person transmission not occurred but it’s need of continuous
survey, in the help of the infection control measures.
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Objectives: Limited natural history data are available in the subpopulation of
patients with CF due to nonsense mutations (nmCF). Longitudinal data from the
placebo group of a 48-week Phase 3 clinical trial of the investigational new drug,
ataluren, are provided to understand the inﬂuence of P. aeruginosa (PA) infection
in nmCF patients.
Methods: Eligibility criteria included age 6 years, sweat chloride >40 mEq/L,
FEV1 40% and 90% of predicted in patients with nmCF. Outcome measures
included spirometry and pulmonary exacerbation rate.
Results: 103 patients completed 48 weeks of blinded study treatment and had a
valid Week 48 spirometry measurement. PA status was determined from clinical
history reports. 45 (44%) of patients had a history of PA infection, 69% of whom
used inhaled antibiotics. Mean age was 23.2 years [SD=9.1] and mean baseline %
predicted FEV1 was 60.5 [SD=15.1], declining to 56.3 [SD=16.6] in those with
a history of PA. In those without a history of PA, 48% used inhaled antibiotics,
mean age was 24.5 years [SD=9.8] and mean baseline % predicted FEV1 was
60.1 [SD=15.2], declining to 56.3 [SD=16.9]. Over 48 weeks, the pulmonary
exacerbation rate was 1.83 [CI=1.19–2.47] for patients with a history of PA and
1.79 [CI=1.04–1.98] for those without.
Conclusion: Data from the placebo arm of an international study of ataluren suggest
there is no difference between PA positive and negative status on FEV1 decrement
or pulmonary exacerbation rate in nmCF patients over 1 year, with a signiﬁcant
proportion of PA negative patients using chronic inhaled antibiotics. Interpretation
of these results is limited by the retrospectively deﬁned nature of PA infection.
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Objectives: Pseudomonas aeruginosa is a common isolate in CF patients. Routine
susceptibility testing of these organisms has been shown to have a high variability
between laboratories, and within the same laboratory. A poor correlation between
susceptibility results and clinical response has been shown. The Cystic Fibrosis
Trust now states that the omission of susceptibility testing for these isolates can be
clinically justiﬁed. Currently in our laboratory susceptibility testing is performed
monthly. The aim of this study was to investigate the impact of the results on patient
management.
Methods: The laboratory results and antibiotic treatment were reviewed for patients
in whom P. aeruginosa was isolated, using the databases of the laboratory and the
CF team, over the period of one year.
Results: 320 specimens from 54 patients were reviewed. Susceptibility testing was
done for 252 specimens (78.8%). There were 255 treatment episodes, in 116 a
susceptibility result was available. In 37 episodes (32%) none of the antibiotics
used were in retrospect found to be active by susceptibility testing, in 14 (38%)
treatment was changed, in nine (24%) due to an allergic reaction, in four (11%)
because of a lack of clinical improvement, in one (3%) due to the susceptibility
testing. In four cases a different antibiotic regimen was used in the next treatment
episode, which was active according to the previous susceptibility proﬁle.
Conclusion: The impact of susceptibility testing on the choice of antibiotic was
small. In accordance with the recommendations from the Cystic Fibrosis Trust it
seems safe and appropriate to reduce the frequency of susceptibility testing to 3
monthly.
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Objectives: The aim of this study was to characterize S. aureus isolates from
patients of Prague Cystic Fibrosis Centre.
Methods: Altogether, 242 respiratory isolates of S. aureus from 105 patients with
CF were collected in 2011–2012. The isolates were typed by PFGE and screened for
susceptibility to antibiotics and presence of resistance and virulence genes. Small
colony variants (SCV) were identiﬁed and tested for auxotrophy.
Results: Total of 142/58 (isolates/patients) were resistant to MLSb antibiotics
(Macrolides-Lincosamides-Streptogramin B), 25/13 were resistant to aminoglyco-
sides and 6/5 were MRSA. MLSb resistance was associated with genes from erm
family or msrA gene. Isolates resistant to aminoglycosides harboured aadC, aphA3
or aac-aphD gene. mecA gene was detected in all of 6 MRSA isolates.
Most frequent virulence genes detected in the isolates (n = 242) were genes for
enterotoxins seg (n = 137), sei (n = 128), sec (n = 38), sea (n = 19), sej (n = 15) and
seh (n = 18). Other virulence genes were not found or found sporadically. Isolates
with SCV phenotype (n = 19), all thymidine auxotrophs, were isolated in 9 patients.
Isolates were separated in to the 39 different pulsotypes by PFGE with two dominant
pulsotypes of 61 isolates from 27 patient (26%) and 28 isolates from 10 patients
(12%) respectively.
Conclusion: This was the ﬁrst study focussing on S. aureus isolates from patients
with CF in the Czech Republic. Our results show high prevalence of MLSb
resistance (55%). Prevalence of SCV isolates was about 9%.
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